OncoSec Medical Inc (ONCSQ)

[guti]

Punit might have unexpectedly given a hint of what’s to come in the following months, when interviewed.
"There is a ton of opportunities that we have in 2016 and beyond. I think where we are really focused on is this next year is going to be a pivotal year for clinical data highlighting this combination approach. One of the key trials that we have ongoing right now is a phase 2 clinical trial in metastatic melanoma with combining Keytruda, Merck’s anti PD-1, with ImmunoPulse IL-12. That trial is…we expect that patients are going to have a better clinical response than with Keytruda alone. In fact we are going after these patients that typically would not respond."